Human trials of Oxford coronavirus vaccine paused over ‘spinal-cord disease fears’
Leaked report says volunteer in UK was left unable to walk after receiving two doses

Human trials of the Oxford coronavirus vaccine are facing delays in the US after a participant suffered a rare neurological condition, according to a leaked document.
The AstraZeneca report, seen by CNN, shows that the decision to pause the trials in early September was made after a previously healthy 37-year-old woman who had received two doses developed transverse myelitis, an inflammation of the spinal cord that can cause paralysis.
The unidentified UK-based volunteer was given the jabs in June and August but was hospitalised after she started to suffer “difficulty walking, pain and weakness in her arms and a headache after tripping while running in September”, the Daily Mail reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
She is understood to have recovered fully.
The internal report by AstraZeneca, which owns the rights to the so-called AZD1222 vaccine, also reveals that the trials had been stopped before after another participant developed transverse myelitis.
“The first pause, in July, was not publicly revealed and the trial was restarted after it was determined the volunteer had multiple sclerosis, a condition that can cause the same neurological reaction,” says The Telegraph.
Following the latest hold-up, trials have resumed in the UK, Brazil, India and South Africa, but remain suspended in the US.
The “concerns around neurological side-effects” of vaccines are “especially sensitive in the US”, according to the newspaper, which notes that an emergency influenza vaccine issued in 1976 caused 450 cases, of which 30 were fatal, of Guillain-Barre syndrome, which also causes inflammation of the spinal cord.
The US Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are reportedly “seeking to determine” what caused the case of transverse myelitis in the Covid trials before giving the green light for the testing to resume.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
How to create a healthy 'germier' home
Under The Radar Exposure to a broad range of microbes can enhance our immune system, especially during childhood
-
George Floyd: Did Black Lives Matter fail?
Feature The momentum for change fades as the Black Lives Matter Plaza is scrubbed clean
-
National debt: Why Congress no longer cares
Feature Rising interest rates, tariffs and Trump's 'big, beautiful' bill could sent the national debt soaring
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Unraveling autism: RFK Jr.'s vow to find a root cause
Feature RFK Jr. has vowed to find the root cause of the 'autism epidemic' in months. Scientists have doubts.
-
The sneaking rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year